- Company
- The popular Daewoong's Nabota
- by Nov 14, 2022 06:06am
- Daewoong Pharmaceutical's botulinum toxin drug Nabota exceeded $100 million in cumulative sales in North America this year. This is an increase of 61% compared to the previous year. According to the earnings report of Daewoong Pharmaceutical partner Evolus on the 9th (local time), Jeuveau, which is sold by the company, recorded cumulative sal
- Product
- Opening of FAPA (The Federation of Asian Pharmaceutical Asso
- by Kim JiEun Nov 11, 2022 05:52am
- An academic festival of Asian Pharmacists was held in Kuala Lumpur, Malaysia. The interest of the Asian pharmacist community was also by far the digital great transformation of infectious diseases caused by COVID-19. On the 10th FAPA ( Asia Pharmaceutical Federation) and the academic competition center were opened at the Cala Convention Cente
- Product
- KMA proposes preconditions for non-face-to-face treatment
- by Kang, Shin-Kook Nov 11, 2022 05:52am
- Regarding the bill that allows non-face-to-face treatment that was recently submitted by the ruling party, the medical community asked the government to actively engage in communication with interested parties in the legislation process, as the systemic side effects should be addressed first. On the 10th, the Korean Medical Association (C
- Company
- Daewoong obtained an item license for Fexuclu
- by Nov 11, 2022 05:52am
- Daewoong Pharmaceutical announced on the 10th that Fexuclu, a new drug for gastroesophageal reflux disease, obtained an item license from the Philippines FDA on the 3rd. The approval was made about eight months after submitting an application for item permission (NDA) at the end of February. It takes about three years to obtain an item licens
- Company
- SK Biopharm’s Q3 sales rise 270% with rise in Xcopri sales
- by Nov 11, 2022 05:51am
- SK Biopharmaceutical’s sales rose greatly in Q3 with the rising sales of its new anti-epileptic drug ‘Xcopri (cenobamate)’ in the US. On the 10th, SK Biopharmaceutical announced sales of KRW 88.8 billion in Q3 this year, a 270.9% on-year increase. The company also reported an operating loss of KRW 9.2 billion in the same period. A
- Policy
- Some companies give up negotiations to recover Strepto
- by Lee, Tak-Sun Nov 11, 2022 05:51am
- Some pharmaceutical companies with the anti-inflammatory enzyme Streptokinase-streptodornase have conveyed to the NHIS that they are not willing to negotiate. Currently, about five of the 37 pharmaceutical companies subject to negotiation are known to have given up negotiations. However, as the end of the negotiations approaches, more phar
- Company
- Impinzi's indication is expected to be approved in Korea
- by Eo, Yun-Ho Nov 10, 2022 05:46am
- Impinzi is also expected to have options for treating immuno-cancer drugs in the area of biliary tract cancer. According to related industries, the Ministry of Food and Drug Safety is reviewing the expansion of biliary tract cancer indications of Imfinzi, an immuno-cancer drug before PD-L1 inhibition mechanism. Permission is possible as early
- Policy
- Will expedited listing be possible within the year?
- by Lee, Tak-Sun Nov 10, 2022 05:46am
- The implementation of the measure that allows expedited listing for serious disease treatments is expected to be deferred somewhat. Although the government started the opinion collection process with the goal of implementing the measure in November, government officials see the measure to be implemented at the end of December at the ear
- Company
- Samjin-Pin to co-develop new targeted protein degrader
- by Lee, Seok-Jun Nov 10, 2022 05:46am
- Samjin Pharm announced on the 9th that it had signed a strategic Memorandum of Understanding (MOU) with the new drug developer Pin Therapeutics to develop a radical and improved treatment for cancer and fibrosis. Under the MOU, Samjin Pharm will conduct a comprehensive study on the targeted protein degrader (TPD) candidate to assess its
- Opinion
- [Reporter's view] COVID-19 demand has disappeared
- by Nov 10, 2022 05:45am
- The boom of pharmaceutical companies, which had benefited from COVID-19, has subsided since the third quarter. Representatively, Roche Group suffered a sharp drop in sales of diagnostic kits and treatments in the third quarter. Roche Group supplies Actemra and Ronapreve, a treatment for COVID-19, and Roche Diagnostics manufactures a COVID-19
